Elevance Health, Inc. (NYSE:ELV) Shares Sold by Rothschild Investment LLC

Rothschild Investment LLC trimmed its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 17.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 635 shares of the company’s stock after selling 133 shares during the period. Rothschild Investment LLC’s holdings in Elevance Health were worth $234,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Raelipskie Partnership acquired a new position in Elevance Health during the 3rd quarter valued at about $26,000. Crews Bank & Trust acquired a new position in shares of Elevance Health during the fourth quarter valued at approximately $34,000. Dunhill Financial LLC increased its stake in shares of Elevance Health by 57.8% during the third quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock valued at $37,000 after acquiring an additional 26 shares during the period. Peterson Financial Group Inc. acquired a new position in shares of Elevance Health during the third quarter valued at approximately $44,000. Finally, Financial Perspectives Inc acquired a new position in shares of Elevance Health during the fourth quarter valued at approximately $50,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Price Performance

NYSE ELV opened at $402.95 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The firm has a market capitalization of $91.61 billion, a price-to-earnings ratio of 15.73, a price-to-earnings-growth ratio of 1.18 and a beta of 0.83. The company has a 50 day simple moving average of $386.22 and a 200-day simple moving average of $441.32. Elevance Health, Inc. has a 52-week low of $362.21 and a 52-week high of $567.26.

Elevance Health (NYSE:ELV) last issued its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. Equities research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be paid a $1.71 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 dividend on an annualized basis and a yield of 1.70%. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. Elevance Health’s payout ratio is 26.71%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ELV. Argus reiterated a “hold” rating and set a $405.40 price target on shares of Elevance Health in a research report on Wednesday, January 29th. Truist Financial lowered their target price on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Barclays lifted their target price on Elevance Health from $501.00 to $512.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Wells Fargo & Company lowered their price objective on shares of Elevance Health from $483.00 to $478.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $485.00 price objective on shares of Elevance Health in a research note on Friday, January 24th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $517.03.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.